Trastuzumab deruxtecan monotherapy shows systemic as well as intracranial effectiveness in patients with previously treated ERBB2-mutant NSCLC.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/trastuzumab-deruxtecan-effective-erbb2-mutant-nsclc-2025a1000vv4?src=rss
Author :
Publish date : 2025-11-17 09:30:00
Copyright for syndicated content belongs to the linked Source.
